MA44965B1 - Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 - Google Patents
Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3Info
- Publication number
- MA44965B1 MA44965B1 MA44965A MA44965A MA44965B1 MA 44965 B1 MA44965 B1 MA 44965B1 MA 44965 A MA44965 A MA 44965A MA 44965 A MA44965 A MA 44965A MA 44965 B1 MA44965 B1 MA 44965B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- pyridinyl derivatives
- aoc3 inhibitors
- aoc3
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne de nouveaux dérivés de pyridinyle de formule (i) dans laquelle r1 et a sont tels que définis dans la description et les revendications, leur utilisation en tant que médicaments, des procédés pour leur utilisation thérapeutique et des compositions pharmaceutiques les contenant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16169356 | 2016-05-12 | ||
| PCT/EP2017/060890 WO2017194453A1 (fr) | 2016-05-12 | 2017-05-08 | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44965A MA44965A (fr) | 2019-03-20 |
| MA44965B1 true MA44965B1 (fr) | 2021-02-26 |
Family
ID=55967162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44965A MA44965B1 (fr) | 2016-05-12 | 2017-05-08 | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9926292B2 (fr) |
| EP (1) | EP3455216B1 (fr) |
| JP (1) | JP6639702B2 (fr) |
| KR (1) | KR20190003995A (fr) |
| CN (1) | CN109153664B (fr) |
| AR (1) | AR108462A1 (fr) |
| AU (1) | AU2017262707B2 (fr) |
| CA (1) | CA3023805A1 (fr) |
| CL (1) | CL2018003158A1 (fr) |
| CO (1) | CO2018012020A2 (fr) |
| CY (1) | CY1123744T1 (fr) |
| DK (1) | DK3455216T3 (fr) |
| EA (1) | EA037188B1 (fr) |
| ES (1) | ES2844926T3 (fr) |
| HR (1) | HRP20202078T1 (fr) |
| HU (1) | HUE053312T2 (fr) |
| IL (1) | IL262662B (fr) |
| JO (1) | JOP20170115B1 (fr) |
| LT (1) | LT3455216T (fr) |
| MA (1) | MA44965B1 (fr) |
| MX (1) | MX379327B (fr) |
| PE (1) | PE20190151A1 (fr) |
| PH (1) | PH12018502376B1 (fr) |
| PL (1) | PL3455216T3 (fr) |
| PT (1) | PT3455216T (fr) |
| RS (1) | RS61256B1 (fr) |
| SA (1) | SA518400393B1 (fr) |
| SG (1) | SG11201809687TA (fr) |
| SI (1) | SI3455216T1 (fr) |
| TW (1) | TWI746551B (fr) |
| UA (1) | UA121930C2 (fr) |
| WO (1) | WO2017194453A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3781166A1 (fr) * | 2018-04-17 | 2021-02-24 | Boehringer Ingelheim International GmbH | Composition pharmaceutique, méthodes de traitement et utilisations associées |
| WO2020083264A1 (fr) * | 2018-10-22 | 2020-04-30 | 广东东阳光药业有限公司 | Dérivé de guanidine et ses applications |
| BR112021004635A2 (pt) * | 2018-10-29 | 2021-05-25 | Boehringer Ingelheim International Gmbh | derivados de piridinil sulfonamida, composições farmacêuticas e usos das mesmas |
| CN112955214B (zh) | 2018-10-29 | 2024-05-07 | 勃林格殷格翰国际有限公司 | 吡啶基磺酰胺衍生物、药物组合物及其用途 |
| IL292416B2 (en) | 2019-10-29 | 2025-07-01 | Eccogene Shanghai Co Ltd | SSAO inhibitors and their use |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19518073A1 (de) * | 1995-05-17 | 1996-11-21 | Hoechst Ag | Substituierte Benzyloxycarbonylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| JP5010917B2 (ja) * | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| DE602005013793D1 (de) * | 2004-07-27 | 2009-05-20 | Astellas Pharma Inc | Thiazolderivate mit vap-1-hemmender wirkung |
| KR20120083292A (ko) * | 2009-09-16 | 2012-07-25 | 아스테라스 세이야쿠 가부시키가이샤 | 글리신 화합물 |
| PT3002278T (pt) * | 2011-03-15 | 2017-06-29 | Astellas Pharma Inc | Composto de guanidina |
| JP6809464B2 (ja) | 2015-08-06 | 2021-01-06 | 宇部興産株式会社 | 置換グアニジン誘導体 |
-
2017
- 2017-05-08 PE PE2018002340A patent/PE20190151A1/es unknown
- 2017-05-08 AU AU2017262707A patent/AU2017262707B2/en not_active Ceased
- 2017-05-08 MX MX2018013701A patent/MX379327B/es unknown
- 2017-05-08 ES ES17721706T patent/ES2844926T3/es active Active
- 2017-05-08 EA EA201892539A patent/EA037188B1/ru not_active IP Right Cessation
- 2017-05-08 HR HRP20202078TT patent/HRP20202078T1/hr unknown
- 2017-05-08 LT LTEP17721706.4T patent/LT3455216T/lt unknown
- 2017-05-08 JP JP2018559351A patent/JP6639702B2/ja active Active
- 2017-05-08 DK DK17721706.4T patent/DK3455216T3/da active
- 2017-05-08 PL PL17721706T patent/PL3455216T3/pl unknown
- 2017-05-08 RS RS20201583A patent/RS61256B1/sr unknown
- 2017-05-08 KR KR1020187035976A patent/KR20190003995A/ko not_active Abandoned
- 2017-05-08 PT PT177217064T patent/PT3455216T/pt unknown
- 2017-05-08 SI SI201730584T patent/SI3455216T1/sl unknown
- 2017-05-08 WO PCT/EP2017/060890 patent/WO2017194453A1/fr not_active Ceased
- 2017-05-08 CA CA3023805A patent/CA3023805A1/fr active Pending
- 2017-05-08 EP EP17721706.4A patent/EP3455216B1/fr active Active
- 2017-05-08 CN CN201780027576.9A patent/CN109153664B/zh active Active
- 2017-05-08 SG SG11201809687TA patent/SG11201809687TA/en unknown
- 2017-05-08 HU HUE17721706A patent/HUE053312T2/hu unknown
- 2017-05-08 MA MA44965A patent/MA44965B1/fr unknown
- 2017-05-08 UA UAA201812102A patent/UA121930C2/uk unknown
- 2017-05-08 US US15/588,739 patent/US9926292B2/en active Active
- 2017-05-11 AR ARP170101262A patent/AR108462A1/es not_active Application Discontinuation
- 2017-05-11 TW TW106115558A patent/TWI746551B/zh not_active IP Right Cessation
- 2017-05-11 JO JOP/2017/0115A patent/JOP20170115B1/ar active
-
2018
- 2018-10-29 IL IL262662A patent/IL262662B/en unknown
- 2018-11-06 CO CONC2018/0012020A patent/CO2018012020A2/es unknown
- 2018-11-07 SA SA518400393A patent/SA518400393B1/ar unknown
- 2018-11-08 CL CL2018003158A patent/CL2018003158A1/es unknown
- 2018-11-12 PH PH12018502376A patent/PH12018502376B1/en unknown
-
2021
- 2021-01-19 CY CY20211100039T patent/CY1123744T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50240B1 (fr) | Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation | |
| MA42230A (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA42231B1 (fr) | Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA45782B1 (fr) | Modulateurs du récepteur de cxcr7 pipéridine | |
| MA38099A1 (fr) | Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4 | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA45222A (fr) | Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| WO2019035863A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA42109B1 (fr) | Amides hétérocycliques utilisés en tant qu'inhibiteurs de kinase | |
| MA40893B1 (fr) | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées | |
| MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
| MA44965B1 (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
| MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| MA46229B1 (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA38287B1 (fr) | Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer | |
| MA40875A (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
| MA38190A2 (fr) | Inhibiteurs d'autotaxine | |
| MA38679B1 (fr) | Modulateurs du récepteur de cxcr7 | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA56098B1 (fr) | Immunomodulateurs hétérocycliques autant qu'inhibiteurs de pdl1 |